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EARLY MIXED CHIMERISM DOES NOT ALTER LONG-TERM PROGNOSIS
FOR PATIENTS RECEIVING IV BUSULFAN-FLUDARABINE (IV BU-FLU)
WITH ALLOGENEIC STEM CELL TRANSPLANTATION FOR AML/MDS
Tang, X.1, de Lima, M.2, Wei, W.2, Chiattone, A.2, Thall, P.F.3,
Medeiros, L.J.4, Rondon, G.2, Shpall, E.J.2, Jones, R.B.2, Nieto, Y.2,
Alousi, A.2, Champlin, R.E.2, Andersson, B.S.2 1Jiangsu Institute of
Hematology, Soochow, China; 2UT MD Anderson Cancer Center,
Houston, TX; 3UT MD Anderson Cancer Center, Houston, TX; 4UT
MD Anderson Cancer Center, Houston, TX
Achieving a full versus a mixed chimeric state has been associated
with a more favorable outcome after allogeneic stem cell transplan-
tation (allo-SCT) for leukemia.Wewere intrigued by what appeared
to be a high incidence of early (SCT day+30) mixed chimerism, yet
a low incidence of serious toxicity and aGvHD, coupled with excel-
lent overall (OS) and disease-free survival (DFS), especially for pa-
tients transplanted in remission (CR or CRp), when using the
reduced-toxicity IV Bu-Flu regimen described by de Lima et al
(BLOOD 2004;104:857-64). We hypothesized that use of a highly
sensitive PCR-based chimerism assessment technique, as well as sep-
arate assaying of myeloid- and T-cell chimerism, might provide
more reliable data for assessing the prognostic value of chimerism
for overall (OS) and disease-free survival (DFS) after allo-SCT.
Patients and Methods: Chimerism assay was performed with
a PCR-based technique to assess microsatellite polymorphism of in-
formative loci, and multi-variate Cox models including chimerism
and other covariates were fit for OS and DFS (Table 1).
Results: 206 AML/MDS patients received Flu at 40mg/m2 daily for
4 days, each dose followed by IV Bu, either at 130mg/m2 or pharma-
cokinetically targeted to an average daily systemic exposure of 6,000
mMol-min. There were 108 males and 98 females, median age of 47
years (16-66). Sixty-six were in first CR, 48 in second CR, 18 had 1st
refractory relapse, 20 were in 1st or 2nd untreated relapse, 37 had in-
duction failures, and 17 high-risk MDS. One patient died before day
+30 and so did not have chimerism studies. The median follow-up of
patients still alive is 5.5 yrs (range 1.3 - 8.6); 193 patients who en-
grafted and were in CR on day +30 had chimerism analyses; 64%
were full chimeras, 36% were mixed chimeras (i.e. $ 1% host cell
DNA). Achieving CR after SCT was important, as was a cytogenetic
‘‘high-risk’’ subgroup (mainly -5/-7, Ph+, or complex chr. abnormal-
ities). However, in the multivariate model neither higher age nor at-
tainment of full vs. mixed donor chimerism by day +30 were of
additional predictive value for either OS or DFS.
We conclude that when the reduced-toxicity IV Bu-Flu regimen is
used for AML/MDS only cytogenetic subgroup (high-risk/others)
and disease state (CR/No CR) but neither patient age nor chimeric
state by SCT day +30 were independently predictive of an altered
prognosis relative to OS and DFS.
Table 1.
95% HazardParameter b SE(b) P-valueHazard
RatioRatio Confidence
LimitsAge (1 yr increase) 0.002 0.009 0.82 1.00 0.99 1.02D+30 chimerism (yes vs. no) -6.68 4.94 0.18 0.001 0.00 20.32D+30 chimerism (magnitude) 0.064 0.050 0.20 1.07 0.97 1.18Cytog risk (Bad vs. others) 0.42 0.20 0.035 1.52 1.03 2.23Disease status at Tx
(CR/CRp vs. others)-0.89 0.21 <.0001 0.41 0.27 0.61414
SAFETY AND UTILITY OF LIVER BIOPSY IN ALLOGENEIC HEMATOPOI-
ETIC STEM CELL TRANSPLANT RECIPIENTS WITH LIVER DYSFUNCTION
Benjamin, H., Costa, R., Tiriveedhi, L., Rossetti, J., Sahovic, E., Lister, J.
Western Pennsylvania Cancer Institute, Pittsburgh, PA
Background: Liver disease is a common, often complex complica-
tion of allogeneic hematopoietic stem cell transplantation (HSCT)
with multi-factorial etiology. Accurate diagnosis is typically made
using a combination of clinical, laboratory and radiological data, as-
sisted by a knowledge of risk factors for particular liver disease.Methods: To evaluate the safety and utility of liver biopsy in this
population, we reviewed data of 45 allogeneicHSCTand donor lym-
phocyte infusion (DLI) recipients who underwent liver biopsy for
hepatic dysfunction of unclear etiology from 1995 to 2006. Seven pa-
tients had the procedure performed more than once, yielding a total
number of 55 studies.
Results: Time to liver biopsy and liver function studies prior to the
procedure were analyzed with patient characteristics depicted in the
table below. As a result of this procedure, graft versus host disease
(GVHD) was confirmed in 23/49 (47%) of suspected cases and sinu-
soidal obstructive syndrome (SOS) was confirmed in 1/3 (33%) of
suspected cases. Similarly, infection and disease relapse were present
in only 33% and 29% of suspected cases, respectively. Drug toxicity,
however, was confirmed in 12/20 (60%) of suspected cases. The pro-
cedure was helpful in modifying or continuing current therapy in
40% of the cases. A total of 13% of the procedures had associated
complications including capsular perforation with fatal hemorrhage
(n 5 2, 4%).
Conclusions: While not without risk, liver biopsy findings con-
firmed or refuted the clinical diagnosis in 60% of cases. This infor-
mation was used tomodify therapy in 40%of cases.Whether the risk
of liver biopsy is justified by the benefit of therapeutic change
remains to be demonstrated by further investigation.
Table 1. Patient CharacteristicsPatients n 5 45
Mean age (range) 42.8 (20-64)
Sex (M/F) 32/13
Disease
ALL 4 (9%)
AML 7 (16%)
CML 9 (20%)
Hodgkin’s Lymphoma 4 (9%)
Non-Hodgkin’s Lymphoma 13 (29%)
MDS 7 (16%)
Multiple Myeloma 1 (2%)ALL indicates Acute Lymphocytic Leukemia, AML: Acute Myelogenous
Leukemia; CML: Chronic Myeloid Leukemia; MDS: Myelodysplastic
Syndrome415
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PA-
TIENTS WITH LIGHT RENAL FAILURE
Oshima, K.1,10, Kanda, Y.1,10, Nanya, Y.2,10, Tanaka, M.3,10,
Nakaseko, C.4,10, Yano, S.5,10, Fujisawa, S.6,10, Fujita, H.7,10,
Takahashi, S.8,10, Kanamori, H.3,10, Okamoto, S.9,10 1Saitama Medical
Center, Jichi Medical University, Saitama, Japan; 2University of Tokyo,
Tokyo, Japan; 3Kanagawa Cancer Center, Kanagawa, Japan; 4Chiba
University School of Medicine, Chiba, Japan; 5 Jikei University School of
Medicine, Tokyo, Japan; 6Yokohama City University Medical Center,
Kanagawa, Japan; 7Yokohama City University Hospital, Kanagawa,
Japan; 8Advanced Clinical Research Center, Institute of Medical Science,
University of Tokyo, Tokyo, Japan; 9Keio University School of Medicine,
Tokyo, Japan; 10Kanto Study Group for Cell Therapy, Japan
Background: Although renal function may affect the outcome of al-
logeneic hematopoietic stem cell transplantation (HSCT),mildly re-
duced renal function which is defined as serum creatinine level
between 1.2 to 2.0 mg/dl did not correlate with non-relapse mortal-
ity (NRM) in the analysis of hematopoietic cell transplantation co-
morbidity index (HCT-CI). Creatinine clearance rate (Ccr) is
a useful and exact way to asses renal function. Impact of renal func-
tion which is evaluated using Ccr before HSCT on the outcome has
not been investigated yet.
Purpose: The aim of this study is to assess the outcome of patients
with mildly reduced renal function which was defined by Ccr before
HSCT.
Method: Patients who underwent allogeneic HSCT using calci-
neurin inhibiter between January, 2004 and December, 2008 at the
seven institutes of Kanto Study Group for Cell Therapy (KSGCT)
with an available Ccr data before HSCT were included in this study.
Poster Session II S305Data were collected and analyzed retrospectively using KSGCT
database and survey sheets.
Results: Four hundred fifty patients (255 males and 195 females)
with a median age of 44-year-old (range 15-68) were included in
this study. All patients had underlying hematological malignancies
except 13 patients with aplastic anemia. Median serum creatinine
level before conditioning was 0.64 (0.32 - 1.33) mg/dl. After correct-
ing the Ccr data by actual body surface area in patients whose body
heights and body weights were available, corrected Ccr was 107 (34 -
372) ml/min/1.73m2. Patients with mildly reduced renal function (\
90 ml/min/1.73 m2) were further classified into group 1 (23 patients,
5.6%) and group 2 (97 patients, 23.7%), according to the corrected
Ccr of 30-59 and 60-89 ml/min/1.73 m2, respectively. Twenty-four
patients (19 patients within 100 days and 5 patients after 100 days)
developed severe renal failure which required hemodialysis after
HSCT. Hemodialysis was discontinued in 5 patients upon recovery
of renal function. Probability of requiring hemodialysis was 13% in
the group 1, which was higher than that in the group 2 (2.1%) and
that in the normal renal function group (6.6%), but the difference
was not statistically significant. The incidences of NRM within 30
days or 100 days after HSCT and grade II to IV acute graft-ver-
sus-host disease did not differ among these three groups.
Conclusion: Similarly to the results of HCT-CI analysis, mildly
reduced renal function before allogeneic HSCT did not affect the
outcome of HSCT.Table 1. Patient, Disease, and Transplantation Characteristics
Characteristic Evaluable-10
Age
Mean 57.5
Range 42-71
Male sex 2
Disease
AML 8
ALL 2
Time between diagnosis and SCT
Mean 446.4
Range 161-1683
Donor
MRD 4
MUD 6
Cohort 1A 6
Cohort 2A 3
Cohort 1B 1
Cycles of chemotherapy prior to SCT
Mean 4
Range 2-9
Bone marrow blasts at starting CPX
Mean 50
Range 8-83
Circulating blasts at starting CPX
Mean 33.4
Range 0-49
CD 34 cell dose infused  10^6/kg
Mean 5.9
Range 3.59-10.17416
THE STEMEX PHASE II/III STUDY: CHALLENGES IN PRODUCTION AND
DELIVERY OF CENTRALLY MANUFACTURED EX VIVO EXPANDED
UMBILICAL CORD BLOOD (UCB) CD133+ CELLS TO PATIENTS WITH
ADVANCED HEMATOLOGICAL MALIGNANCIES
Snyder, D., Landau, E., Rosenheimer, N.G., Mandel, J., Glukhman, E.,
Hasson, N., Lador, C., Olesinski, E., Hagler-Price, G., Leshem, A.,
Freind, E., Ben Abu, K., Sharabi, S., Shachaf, O., Israeli, H.,
Harati, D., Srur-Kidron, O., Bracha, D., Peled, T. Gamida Cell Ltd.,
Jerusalem, Israel
Use of UCB as an alternative SC source is limited due to inade-
quate TNC&CD34+ cells, in that it is often difficult to find a single
unit for successful engraftment in adolescents & adults. One strategy
to overcome this limitation is to increase the number of cells by ex-
pansion of HPC. StemExwas developed as a cell graft based on use
of a copper chelator (TEPA) that delays differentiation & promotes
expansion of HPC with engraftment capabilities. StemEx is manu-
factured from a fraction of a single CBU originally frozen in 2 sep-
arate fractions. CD133+ progenitor cells purified from the smaller
or equal fraction are cultured for 21 days with cytokines & TEPA.
The product is transplanted to the patient 24h after infusion of the
unmanipulated fraction. A global pivotal Phase II/III registration
study is underway to evaluate the safety & efficacy of StemEx in
patients with advanced hematological malignancies.
Taking into consideration the variability in the intrinsic potential
& the cryopreservation processes of the CBUs, successful & robust
manufacturing of clinical batches is one of the major challenges of
this study. 61 StemEx batches have been manufactured so far in 3
centralized GMP facilities in US, EU & Israel. All the fresh hand-
carried batches were successfully delivered to the centers within
the StemEx stability period. Of the 61 batches, 58 successfully passed
the in-process & final process quality control (IPQC & FPQC) cri-
teria: median fold expansion of TNC, CD34+ cells & CFU over cul-
ture input values were 377 (52-743, n 5 58), 74 (6-206, n 5 57) &
111 (43-662, n 5 56), respectively. Expansion of only a portion of
the CBU resulted in a median 9.6 fold increase (0.8-90.3 n 5 58)
in the total number of CD34+ cells infused, over the theoretical num-
ber of CD34+ cells that would be infused from the entire CBU with-
out expansion. Interestingly, all three batches that failed to expand
also did not pass the IPQC criteria:$ 10 CFU/1000 freshly purified
CD133+ cells at day 0 of production. This information, available be-
fore initiation of patient myeloablation, provides further confidence
regarding the quality of the CBU & the StemEx product.
With the significant production challenges of an ex vivo expanded
product being successfully met in the current registration trial, Ste-
mEx study demonstrates the feasibility of this approach in satisfying
an urgent unmet clinical need in the UCB transplantation setting.417
A NOVEL SEQUENTIAL TREATMENT UTILIZING CPX-351 AS SALVAGE
CHEMOTHERAPY FOLLOWED BY A REDUCED INTENSITY CONDITIONING
ALLOGENEIC STEM-CELL TRANSPLANTATION FOR PATIENTS WITH
REFRACTORY LEUKEMIA
Gergis, U., Ritchie, E., Roboz, G.J., Scandura, J.M., Mayer, S.,
Mark, T.M., Shore, T.B., Wissa, U., Feldman, E.J. Weill Cornell
Medical College, New York, NY
Cytoreduction followed by Reduced Intensity Conditioning
(RIC) may lead to improved results in allogeneic stem cell transplant
(SCT) for refractory leukemia. CPX-351 is a novel liposomal formu-
lation that encapsulates the combination of cytarabine and daunoru-
bicin in a fixed 5: 1 ratio. In vitro, it selectively concentrates in the
marrow. Clinically, CPX-351 is well tolerated, with a favorable tox-
icity profile. In a phase I trial, patients with refractory acute leukemia
were treated with escalating doses of CPX-351 starting at 60 mg/m2
on days - 28, -26 and -24 followed by RIC with IV busulfan 3.2 mg/
kg/day on days -6 to -3 and fludarabine 30 mg /m2/day on days -6 to
-3 (Bu/Flu). GVHD prophylaxis with tacrolimus and methotrexate.
The protocol was amended to include a second arm, B to shorten the
duration prior to stem cell infusion to 3 weeks. Fifteen patients
(AML-12, ALL-2, CML in blast crisis-1) have been enrolled to
date. Five patients are inevaluable due to short follow up (2), sepsis
resulting in aborted transplant plans (2) and donor’s unavailability
(1). Ten patients underwent SCT are evaluable (AML-8, ALL-2).
All patients received HLA compatible grafts (MUD-8, MRD-2).
Three patients had primary induction failure and 7 had relapsed re-
fractory disease. All evaluable patients achieved adequate neutrophil
engraftment at a mean of 16.6 days (range 12-35). Nine patients
achieved adequate platelet engraftment at a mean of 15.8 days (range
11-33). Eight patients achieved complete hematologic and cytoge-
netic remission upon full blood counts recovery. One patient had
full neutrophil and platelets engraftment but did not have a bone
marrow biopsy as of this date. Two patients (ALL) had a disease re-
lapse 24 and 60 days post transplant. Acute GVHDoccurred in 3 pa-
tients. One patient with a stage 2 skin GVHD and 2 patients had
stage 3-4 GI GVHD upon cessation of immunosupression 5 and 9
months post transplantation. Grade 3 mucositis developed in 4 pa-
tients.The 100 days overall survival and disease free survival for 8
evaluable patients was 85% and 78% respectively. At a mean follow
